R2GConnect Channels
Digital Therapeutics (DTx) Solutions
Online · Apply by 30 Sept 2026 (GMT+1)
Open calls are for startup accounts. Sign in or create a startup profile →
About this open call
Partner with Pharma to Scale Clinically Validated Digital Therapeutics Are you developing evidence-based Digital Therapeutics that deliver measurable clinical outcomes? R2GConnect invites Digital Therapeutics (DTx) innovators, startups, and scale-ups to apply for a targeted open call connecting them with leading pharmaceutical companies seeking to expand their portfolios with clinically validated, software-driven treatment solutions. What We’re Looking For We are seeking Digital Therapeutics solutions defined as software-based medical interventions designed to prevent, manage, or treat a medical disorder or disease. Solutions should demonstrate clinical relevance and, where applicable, regulatory alignment (e.g., CE-marked or prescription-grade interventions). We are particularly interested in solutions such as: • Prescription Digital Therapeutics (PDTx) or regulated DTx products • Chronic disease management platforms (e.g., cardiometabolic, respiratory conditions) • Evidence-based mental health interventions, including CBT-based digital therapies • Condition-specific therapeutic applications in areas such as neurology, oncology support, and metabolic disease • Integrated digital modules designed to complement or enhance pharmaceutical treatments • Scalable, data-driven interventions with demonstrated clinical or real-world evidence Why Apply? This open call is designed to accelerate collaboration between DTx innovators and pharmaceutical partners actively seeking digital solutions to extend treatment value beyond the pill. Selected companies will: • Pitch directly to pharmaceutical business units, medical affairs, and innovation teams • Join exclusive partner-matching and showcase sessions • Engage in structured 1:1 partnership discussions with Pharma stakeholders • Explore commercial collaboration models, including prescription bundling, co-marketing, and licensing agreements • Gain visibility for potential funding, scaling support, and strategic partnerships Apply today This is an opportunity to position your Digital Therapeutics solution within the pharmaceutical ecosystem and accelerate real-world adoption at scale.
- What’s offered
- Commercial partnershipPilot
- Financial contribution
- Tbd
- Must-have requirements
- a) Clinically validated DTx solution with demonstrated evidence of therapeutic impact (e.g., clinical trials, real-world evidence, or validated health outcomes) in a defined disease area. b) Regulatory and quality readiness, including alignment with medical device requirements where applicable (e.g., CE marking or equivalent) and a clear pathway for compliant deployment in clinical settings. c) Scalable, integration-ready product, capable of being deployed within healthcare or pharma ecosystems, with support for interoperability, secure data handling, and sustained patient engagement.
Who should apply
- Service categories
- Digital therapeutics
- Therapeutic areas
- All therapeutic areas / Disease agnostic
- Regulatory approvals
- CE (MDD/MDR)
- Regions & markets
- APACEurope
- Startup stage
- Growth - Paid PilotsScaling - Expansion
Application questions
- What clinically validated outcome does your solution improve, and what level of evidence supports it?
- How many active users do you have?
- How does your solution integrate into real-world care pathways, scale across healthcare or pharma ecosystems, and what is its current reimbursement status?
- If accepted
- Selected companies will be invited to a pitch presentation and 1:1 discussion with pharma representatives.